L. Etude,

, Ce qu'il faut d'abord souligner, c'est que l'enquête patient et l'enquête pharmacien reposent 6

D. C. Baumgart and W. J. Sandborn, Crohn's disease, Lancet, vol.380, pp.1590-1605, 2012.

I. Ordás, L. Eckmann, M. Talamini, D. C. Baumgart, W. J. Sandborn et al., Lancet, vol.380, pp.1606-1619, 2012.

S. Danese, G. Fiorino, and W. Reinisch, Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-? therapy, Aliment. Pharmacol. Ther, vol.34, pp.1-10, 2011.

M. Fumery, L. Dauchet, C. Vignal, and C. Gower-rousseau, Epidemiology, risk factors and factors associated with disabling course in inflammatory bowel disease

, Rev Prat, vol.64, pp.1210-1215, 2014.

J. Cosnes, C. Gower-rousseau, P. Seksik, and A. Cortot, Epidemiology and natural history of inflammatory bowel diseases, Gastroenterology, vol.140, pp.1785-1794, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00631553

L. Peyrin-biroulet, E. V. Loftus, J. Colombel, and W. J. Sandborn, Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts, Inflamm. Bowel Dis, vol.17, pp.471-478, 2011.

L. M. Fr and . Des, Les maladies inflammatoires chroniques de l'intestin-Le Moniteur des Pharmacies n° 3198 du 11/11/2017-Revues-Le Moniteur des pharmacies.fr. Le Moniteur des pharmacie

. Salazopyrine, . Fivasa, . Pentasa, . Rowasa, and Q. Dipentum,

Y. Wang, C. E. Parker, B. G. Feagan, and J. K. Macdonald, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.000544, 2016.

Y. Wang, C. E. Parker, T. Bhanji, B. G. Feagan, and J. K. Macdonald, Oral 5aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.4, p.543, 2016.

A. K. Waljee, Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study, BMJ, vol.357, p.1415, 2017.

M. E. Sherlock, J. K. Macdonald, A. M. Griffiths, A. H. Steinhart, and C. H. Seow,

, Oral budesonide for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.007698, 2015.

J. W. Mcdonald, D. J. Tsoulis, J. K. Macdonald, and B. G. Feagan, Methotrexate for induction of remission in refractory Crohn's disease, Cochrane Database Syst Rev, vol.12, p.3459, 2012.

B. G. Feagan, Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators, N. Engl. J. Med, vol.332, pp.292-297, 1995.

J. Panés, Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease, Gastroenterology, vol.145, p.1, 2013.

D. S. Kotlyar, Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis, Clin. Gastroenterol
URL : https://hal.archives-ouvertes.fr/hal-00998407

. Hepatol, , vol.13, pp.847-858, 2015.

F. Baert, Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease, Gastroenterology, vol.138, pp.10-11, 2010.

B. G. Feagan, Vedolizumab as Induction and Maintenance Therapy for

, Ulcerative Colitis, New England Journal of Medicine, vol.369, pp.699-710, 2013.

W. J. Sandborn, Vedolizumab as induction and maintenance therapy for Crohn's disease, N. Engl. J. Med, vol.369, pp.711-721, 2013.

B. G. Feagan, Ustekinumab as Induction and Maintenance Therapy for Crohn's

, Disease. N. Engl. J. Med, vol.375, pp.1946-1960, 2016.

, Éducation thérapeutique du patient Définition, finalités et organisation: Juin, Obésité, vol.4, pp.39-43, 2007.

S. De-geest and E. Sabaté, Adherence to long-term therapies: evidence for action, Eur J Cardiovasc Nurs, vol.2, p.323, 2003.

M. Viswanathan, Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review, Ann. Intern. Med, vol.157, pp.785-795, 2012.

F. Bermejo, Factors that modify therapy adherence in patients with inflammatory bowel disease, Journal of Crohn's and Colitis, vol.4, pp.422-426, 2010.

R. Horne, R. Parham, R. Driscoll, and A. Robinson, Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease, Inflamm. Bowel Dis, vol.15, pp.837-844, 2009.

D. K. Tiao, Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn's Disease and Ulcerative Colitis, Inflamm. Bowel Dis, vol.23, pp.1257-1261, 2017.

J. T. Chan, C. Selinger, and V. Kariyawasam, An inflammatory bowel disease clinical pharmacist significantly improves medication acceptance rates through personalised counselling | South Western Sydney Clinical School, J Gastroenterol Hepatol, vol.27, p.99, 2012.

S. V. Kane, J. Chao, and P. M. Mulani, Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients, Adv Ther, vol.26, pp.936-946, 2009.

C. H. Tae, Importance of Patients' Knowledge of Their Prescribed Medication in

, Improving Treatment Adherence in Inflammatory Bowel Disease, J. Clin. Gastroenterol, vol.50, pp.157-162, 2016.

A. Lopez, V. Billioud, C. Peyrin-biroulet, and L. Peyrin-biroulet, Adherence to antiTNF therapy in inflammatory bowel diseases: a systematic review, Inflamm. Bowel Dis, vol.19, pp.1528-1533, 2013.

. Avenir, , p.21, 2018.

Y. Derwa, D. J. Gracie, P. J. Hamlin, and A. C. Ford, Systematic review with metaanalysis: the efficacy of probiotics in inflammatory bowel disease, Aliment. Pharmacol. Ther, 2017.

S. Coenen, Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.23, pp.318-324, 2017.

A. T. Abegunde, B. H. Muhammad, and T. ;. Ali, Effectiveness of disease-specific cognitive-behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD), World Journal of Gastroenterology, vol.22, p.71, 2016.

M. Girardin, First-Line Therapies in Inflammatory Bowel Disease, Digestion, vol.86, pp.6-10, 2012.

F. Colombara, M. Martinato, G. Girardin, and D. Gregori, Higher Levels of

, Knowledge Reduce Health Care Costs in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.21, pp.615-622, 2015.

J. E. Baars, Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer, Digestive and Liver Disease, vol.42, pp.777-784, 2010.

L. Peyrin-biroulet, French national consensus clinical guidelines for the management of Crohn's disease, Digestive and Liver Disease, vol.49, pp.368-377, 2017.

C. P. Selinger, The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease

, Alimentary Pharmacology & Therapeutics, vol.45, pp.63-74, 2017.

K. P. Lesnovska, S. Börjeson, H. Hjortswang, and G. H. Frisman, What do patients need to know? Living with inflammatory bowel disease, Journal of Clinical Nursing, vol.23, pp.1718-1725, 2014.

G. Van-assche, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.4, pp.7-27, 2010.

A. Kornbluth and D. B. Sachar,

, American college of gastroenterology, practice parameters committee, The American journal of gastroenterology, vol.105, pp.501-523, 2010.

C. Abraham and J. H. Cho, Inflammatory bowel disease, N. Engl. J. Med, vol.361, pp.2066-2078, 2009.

S. B. Hanauer, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, vol.359, pp.1541-1549, 2002.

E. Mcdermott, Clinical impact and drivers of nonadherence to maintenance medication for inflammatory bowel disease, Expert Opin Drug Saf, vol.10, pp.863-870, 2011.

, ANNEXE : Annexe 1 : Score de Morisky Green

, Questionnaire patient : Annexe, vol.2

, Tableau des principales disponibles pour le traitement des MICI, vol.4